* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download EA_QA214.4_COCandSJW - Specialist Pharmacy Service
Survey
Document related concepts
Neuropsychopharmacology wikipedia , lookup
Neuropharmacology wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Pharmacokinetics wikipedia , lookup
National Institute for Health and Care Excellence wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmacognosy wikipedia , lookup
Theralizumab wikipedia , lookup
Drug interaction wikipedia , lookup
Transcript
Medicines Q&As Q&A 214.4 Is there an interaction between St John’s Wort and combined and progestogen only hormonal contraceptives Prepared by UK Medicines Information (UKMi) pharmacists for NHS healthcare professionals Before using this Q&A, read the disclaimer at www.ukmi.nhs.uk/activities/medicinesQAs/default.asp Date prepared: 23rd February 2016 Background St John’s Wort (SJW) is the common name for the plant Hypericum perforatum and is a popular herbal remedy for the management of mild to moderate depression [1, 2]. SJW has several active constituents including hypericin, hyperforin and adhyperforin. Initially it was thought that hypericin was responsible for its action; however it is now understood that hyperforin, adhyperforin and several other related compounds are the primary active constituents [1-3]. In vitro studies have shown that hyperforin is a potent inducer of the cytochrome P450 enzymes, particularly CYP3A4, CYP1A2 and CYP2C9 as well as affecting the P-glycoprotein cellular transport system. Small short term studies in human volunteers have failed to confirm this [4, 5]. CYP3A4 is the major route for inactivation of most contraceptive steroids, including ethinylestradiol and most progestogens and enzyme inducers, such as anti-epileptics, can affect this enzyme causing a decrease in serum hormone levels [1, 6-9]. SJW preparations are non-standardised and the exact composition and levels of active constituents, including hyperforin, varies between different preparations, and patients often switch between preparations. Therefore the overall effectiveness and level of enzyme induction will vary and change over time [6-10]. The Committee on Safety of Medicines (CSM) has advised that St John’s Wort (SJW) should not be used with hormonal contraceptives, except intrauterine devices, as there is a risk of contraceptive failure and unplanned pregnancy [10, 11]. Answer Most of the available evidence regarding an interaction between SJW and hormonal contraceptives, relates to women who were taking a combined oral hormonal contraceptive, although there have been a few anecdotal reports with other formulations [7, 8]. It has also been reported that SJW can decrease norethindrone and ethinyl estradiol levels by 13% and 15%, resulting in breakthrough bleeding, irregular menstrual bleeding or unplanned pregnancy [1]. Bleeding irregularities usually occur within a week of starting SJW and regular cycles return when SJW is discontinued [1]. In 1999, 3 cases of breakthrough bleeding were reported in patients taking ethinylestradiol and desogestrel and were attributed to lowered plasma ethinylestradiol concentrations caused by SJW [12, 13]. By 2000, the Swedish Medical Products Agency, had received 8 reports of inter-menstrual bleeding and 1 report of changed menstrual bleeding in women on oral contraceptive tablets who started taking SJW [14, 15]. An unplanned pregnancy in a 36 year old woman taking a regular ethinylestradiol plus dienogestrel oral contraceptive, was reported by Schwarz et al in 2003 [16]. The woman self medicated with up to 1700mg of hypericin extract daily for approximately 3 months prior to conception. Up to October 2015, the CSM had received 16 reports of unintended pregnancy in patients taking SJW [17]. Several studies have assessed the effect of SJW extracts on oral contraceptives. The effect of SJW 300mg three times daily (TDS) in 12 healthy premenopausal women receiving a combined oral contraceptive pill containing norethindrone and ethinylestradiol was assessed over 3 consecutive 28 day menstrual cycles. SJW was associated with increased clearance of norethindrone (8.2 L/h to 9.5L/h, p=0.04) and a reduction in the half life of ethinylestradiol (23.4 to 12.2, p=0.02). Serum concentrations of follicle stimulating hormone, luteinising hormone and progesterone were not Available through NICE Evidence Search at www.evidence.nhs.uk 1 Medicines Q&As significantly affected by SJW. Breakthrough bleeding occurred in 17% (2/12 women) on COC alone vs 58% (7/12) women when on COC and SJW together [18]. Seventeen women who had received a low dose oral contraceptive containing ethinylestradiol and desogestrel for one menstrual cycle, randomly received either 300mg SJW twice daily (BD) or 300mg SJW three times daily (TDS) for one cycle. The groups were then crossed over. There was no significant change in follicle maturation, serum estradiol or progesterone concentrations. More subjects reported intra-cyclic bleeding in the SJW treatment groups, (77% and 88% in the BD and TDS groups; p<0.001 respectively versus 35% in the COC alone group). The study authors concluded that there was no evidence of ovulation during concomitant treatment with SJM, but intra-cyclic bleeding episodes increased which could affect compliance and lead to unintended pregnancies [19]. In a non-randomised, single blind, sequential trial, 16 healthy women received a low dose COC, containing ethinylestradiol and norethindrone acetate for 21 days and placebo for 7 days for 2 consecutive 28 day cycles. SJW 300mg three times daily was then taken concomitantly for 2 additional 28 day cycles. The Area under the Curve (AUC) decreased, resulting in a 13-15% reduction in dose exposure to the oral contraceptives. Breakthrough bleeding occurred in more subjects during the SJW treatment phase than during the control phase (56% vs. 31%; p=0.05). One patient was thought to have ovulated during the control phase compared with 6 patients in the SJW cycle. The study authors concluded that SJW is associated with increased metabolism of norethindrone and ethinylestradiol, breakthrough bleeding, follicle growth and ovulation [20]. In March 2014, the MHRA recommended that women using hormonal contraception, except those using intrauterine devices, should not take herbal products containing SJW, due to an increased risk of unplanned pregnancy [10]. Guidance issued by the Clinical Effectiveness Unit of the Faculty of Sexual and Reproductive Health Care (FSRH), highlights that enzyme inducing drugs, such as SJW have the potential to reduce the efficacy of combined hormonal contraceptives, progestogen only pills, oral emergency contraception and the progestogen only implant. The FSRH advise that women using these formulations should either avoid St John's Wort or they should use an alternative form of contraception, unaffected by enzyme inducers, which according to the FSRH includes: the progestogen only injectable (depot medroxyprogesterone acetate), copper bearing intrauterine devices (Cu-IUDs), the levonorgestrel containing intrauterine device or barrier methods. Health professionals supplying hormonal contraception should ask women about their current and previous drug use including prescription, over the counter, herbal, recreational drugs and dietary supplements. Women using hormonal contraception should be informed about the potential for interactions with other drugs and the need to seek the advice of a health professional before starting any new drugs [21, 22]. The FSRH advice is available also recommends the following if SJW or any liver enzyme inducing medication must be continued: Women on short term treatment with SJW (defined arbitrarily as ≤2 months) may continue using the combined patch, ring or standard strength combined pill, but they should be advised to use additional contraceptive precautions (e.g. condoms) while taking SJW and for 28 days after stopping [21]. To minimise the risk of contraceptive failure the FSRH recommends an extended regimen (taking COC continuously for ≥3 weeks until breakthrough bleeding occurs for 3-4 days) or tricycling (taking 3 pill packets continuously without a break) and a shortened pill/patch or ring free interval of 4 days. Only monophasic 21 day pill packs are suitable for extended use or tricycling and the FSRH recommends a minimum COC strength of 30µg ethinylestradiol (EE) [21]. Women who do not wish to use additional contraception or women on long term treatment (>2 months) with an enzyme inducing drug who do not wish to change to another method may be offered an increased dose of COC containing at least 50µg EE during treatment and for 28 days after stopping [21]. An extended or tricycling regimen with reduced pill free interval of 4 days is recommended but additional contraception is not essential. If breakthrough bleeding occurs, and other causes Available through NICE Evidence Search at www.evidence.nhs.uk 2 Medicines Q&As such as chlamydia are excluded, the dose of EE can be increased up to a maximum of 70µg, use additional precautions or switch to a method unaffected by enzyme inducing drugs [21]. The FSRH also advise that the use of two COCs, extended/tricycling regimens and shortening the pill free interval are all unlicensed and there is no evidence that such practice is effective in women on SJW [21]. There do not appear to have been any clinical pharmacokinetic studies of enzyme inducers, including SJW, with any of the available oral progestogen only contraceptives [8]. There are isolated reports of pregnancies in women given these contraceptives with SJW [8, 17]. The progestogen only pill (POP) or implant may be affected by SJW. Alternative methods of contraception should be used [21]. Concomitant use of SJW with progestogen only injectables does not appear to necessitate additional precautions, dose adjustment or alteration to the dosing /replacement interval. Women using a POP or implant with a short term course of SJW could be offered a one-off injectable progestogen preparation [21]. Summary The interaction between oral contraceptives and St John's Wort appears to be established. Its incidence is not known, but cases of breakthrough bleeding, menstrual irregularity and unplanned pregnancy have been reported. The Committee on Safety of Medicines (CSM) has advised that St John’s Wort (SJW) should not be used with hormonal contraceptives, except intrauterine devices, as there is a risk of contraceptive failure and unplanned pregnancy. Health professionals supplying hormonal contraception should ask women about their current and previous drug use including prescription, over the counter, herbal, recreational drugs and dietary supplements. Women using hormonal contraception should be informed about the potential for interactions with other drugs and the need to seek the advice of a health professional before starting any new drugs including herbal of dietary supplements. The Faculty of Sexual and Reproductive Health Care (FSRH) in the UK, advise that women taking oral contraceptives (both combined and progestogen-only pills) should either avoid St John's Wort or they should use an alternative form of contraception, unaffected by enzyme inducers [e.g. progestogen only injectable, copper bearing intrauterine devices (Cu-IUDs), the levonorgestrel containing intrauterine device or barrier methods]. If St John's Wort is continued, the general guidelines, produced by the FSRH for the use of liver enzyme inducers with hormonal contraceptives should be followed. Limitations This document does not consider the effect of SJW on emergency hormonal contraceptives or on hormonal contraceptives when used for non-contraceptive indications, such as acne or hirsutism. References 1) 2) 3) 4) 5) 6) 7) Jellin J, Gregory P, et al, editors. Natural Medicines Comprehensive Database. St John’s Wort. Last updated 25/01/2016. Accessed 22/02/2016 via http://www.naturaldatabase.com. Taylor D, Paton C, Kerwin R. The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust Prescribing Guidelines. 12th ed. London: Informa Healthcare; 2015, 246-9. Will-Shahab L, Bauer S, Kunter U et al. St John’s Wort extract (Ze117) does not alter the pharmacokinetics of a low dose oral contraceptive. European Journal of Clinical Pharmacology 2009; 65: 287-294. Henderson L, Yue QY, Bergquist C et al. St John’s Wort (Hypericum perforatum): drug interaction and clinical outcomes. British Journal of Clinical Pharmacology 2002; 54: 349-356. Barnes J, Anderson LA et al. St John’s Wort (Hypericum perforatum L.): A review of its chemistry, pharmacology and clinical properties. Journal of Pharmacy and Pharmacology 2001; 53: 583-600. Mannel M. Drug interactions with St John’s Wort: Mechanisms and Clinical implications. Drug Safety 2004; 27: 773-797. Baxter K (ed). Stockley’s Drug Interactions online. Combined Hormonal Contraceptives + St John’s wort (Hypericum perforatum). Last updated 21/05/14. Accessed 22/02/2016 via www.medicinescomplete.com Available through NICE Evidence Search at www.evidence.nhs.uk 3 Medicines Q&As 8) 9) 10) 11) 12) 13) 14) 15) 16) 17) 18) 19) 20) 21) 22) Baxter K (ed). Stockley’s Drug Interactions online. Progestogen only contraceptives; oral + enzyme inducers. Last updated 21/05/2014. Accessed 22/02/2016 via www.medicinescomplete.com Russo E, Scicchitano F, Whalley BJ et al. Hypericum perforatum: Pharmacokinetic, Mechanism of Action, Tolerability and Clinical Drug-Drug Interactions. Phytotherapy Research 2014; 28: 64355. Committee on Safety of Medicines (UK): St John’s wort: interaction with hormonal contraceptives, including implants-reduced contraceptive effect. Drug Safety Update March 2014. https://www.gov.uk/drug-safety-update/st-john-s-wort-interaction-with-hormonalcontraceptives-including-implants Committee on Safety of Medicine. Reminder: St Johns Wort (Hypericum perforatum) interactions. Current Problems in Pharmacovigilance May 2000; 26: 6. Madabushi R, Frank B, Drewelow B et al. Hyperforin in St. John’s Wort drug interactions. European Journal of Clinical Pharmacology 2006; 62: 225-233. Ernst E. Second thoughts about safety of St John’s Wort. Lancet 1999; 354: 2014-2015. Izzo AA. Drug interactions with St John’s Wort (Hypericum perforatum): a review of the clinical evidence. International Journal of Clinical Pharmacology and Therapeutics 2004; 139-148. Yue QY, Bergquist C. Safety of St John’s Wort. Lancet 2000; 355: 576-577. Schwarz UI, Buschel B, Kirch W et al. Unwanted pregnancy on self medication with St John’s Wort despite hormonal contraception. British Journal of Clinical Pharmacology 2003; 55:112-113. Medicines and Healthcare Products Regulatory Agency. Drug Analysis Prints. Hypericum Accessed 22/02/2016. http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYell owCardScheme/YellowCarddata/Druganalysisprints/index.htm Hall SD, Wang Z, Huang, SM et al. The interaction between St John’s Wort and an oral contraceptive. Clinical Pharmacology and Therapeutics 2003; 74: 525-535. Pfrunder A, Schiesser M, Gerber S et al. Interaction of St John’s Wort with low dose oral contraceptive therapy: a randomised controlled trial. British Journal of Clinical Pharmacology 2003; 56: 683-690. Murphy PA, Kern SE, Stanczyk FZ et al. Interaction of St John’s Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinylestradiol, ovarian activity and breakthrough bleeding. Contraception 2005; 71: 402-408. FSRH Clinical Effectiveness unit Clinical Guidance: Drug Interactions with Hormonal Contraception. January 2011 (updated January 2012). Available at http://www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf Accessed 22/02/2016. FSRH: Clinical Effectiveness unit. Statement St John’s Wort and Hormonal Contraception March 2014. Available at http://www.fsrh.org/pdfs/CEUStatementStJohnsWort.pdf. Accessed 22/02/2016. Quality Assurance Prepared by Katie Smith, East Anglia Medicines Information Service (based on earlier work by Victoria Gibson) Date Prepared 23rd February 2016 Checked by Abigail Scott, East Anglia Medicines Information Service Date of check 2nd March 2016 Search strategy Embase: Hypericum perforatum/it + Contraceptive agent Medline: Hypericum + Contraceptive agents PubMed: St John’s Wort + hormonal contraceptives + interaction Cochrane Library: St John’s Wort, contraception Available through NICE Evidence Search at www.evidence.nhs.uk 4 Medicines Q&As NICE Evidence: St John’s Wort, hormonal contraceptives Faculty of Sexual and Reproductive Healthcare: St John’s Wort, contraception Natural Medicines Comprehensive Database: St John’s Wort, depression, oral contraceptives Clinical Knowledge Summaries: contraception, St John’s Wort MHRA Drug Analysis Prints website: St John’s Wort, pregnancy Stockley’s Drug interactions: hormonal contraceptives, St John’s Wort Drugdex: hormonal contraceptives, St John’s Wort British National Formulary, Maudsley Guidelines 12th Ed, Psychotropic drug directory 2014, Martindale, AHFS DI Available through NICE Evidence Search at www.evidence.nhs.uk 5